ULTRAGENYX PHARMACEUTICAL INC. Current Liabilities
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Current Liabilities of $351.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Liabilities, Current $351.00M.
- 2026-03-31: Liabilities, Current $325.00M.
- 2025-12-31: Liabilities, Current $384.00M.
- 2025-09-30: Liabilities, Current $340.02M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $351.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $325.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $384.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $340.02M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $293.24M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $291.67M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $344.00M 10-K · filed 2026-02-18 | $344.15M 10-K · filed 2025-02-19 |
| 2024-09-30 | $285.01M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $272.87M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $245.57M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $280.44M 10-K · filed 2025-02-19 | |
| 2023-09-30 | $253.98M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $244.38M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $218.18M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $261.21M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $227.36M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $220.64M 10-Q · filed 2022-07-29 | |
| 2022-03-31 | $167.23M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $181.37M 10-K · filed 2023-02-17 | |
| 2021-09-30 | $135.93M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $127.07M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $127.04M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $189.61M 10-K · filed 2022-02-15 | |
| 2020-09-30 | $201.19M 10-Q · filed 2020-10-27 | |
| 2020-06-30 | $219.73M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $196.86M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $103.30M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $90.31M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $75.01M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $66.88M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $74.72M 10-K · filed 2020-02-14 | |
| 2018-09-30 | $66.68M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $66.05M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $57.58M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $71.01M 10-K · filed 2019-02-20 | |
| 2017-09-30 | $64.26M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $62.67M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $51.76M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $60.26M 10-K · filed 2018-02-21 | |
| 2016-09-30 | $50.43M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $31.98M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $29.88M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $27.92M 10-K · filed 2017-02-17 | |
| 2015-09-30 | $24.73M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $23.04M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $14.24M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $12.52M 10-K · filed 2016-02-26 | |
| 2014-09-30 | $11.07M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $8.94M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $6.81M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $5.92M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |